PT1419151E - Cristais que incluem um sal do ácido málico de n-[2- (dietilamino)etil]-5-[(5-fluoro-1,2-di-hidro-2-oxo-3hindol- 3-ilideno)metil-2,4-dimetil-1h-pirrol-3-carboxamida, processos para a sua preparação e suas composições - Google Patents

Cristais que incluem um sal do ácido málico de n-[2- (dietilamino)etil]-5-[(5-fluoro-1,2-di-hidro-2-oxo-3hindol- 3-ilideno)metil-2,4-dimetil-1h-pirrol-3-carboxamida, processos para a sua preparação e suas composições Download PDF

Info

Publication number
PT1419151E
PT1419151E PT2759342T PT02759342T PT1419151E PT 1419151 E PT1419151 E PT 1419151E PT 2759342 T PT2759342 T PT 2759342T PT 02759342 T PT02759342 T PT 02759342T PT 1419151 E PT1419151 E PT 1419151E
Authority
PT
Portugal
Prior art keywords
chrystals
ylidene
carboxamide
diethylamino
indole
Prior art date
Application number
PT2759342T
Other languages
English (en)
Portuguese (pt)
Inventor
Thomas J Fleck
Michael Hawley
Stephen P Prescott
Mark T Maloney
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23211067&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1419151(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of PT1419151E publication Critical patent/PT1419151E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
PT2759342T 2001-08-15 2002-08-13 Cristais que incluem um sal do ácido málico de n-[2- (dietilamino)etil]-5-[(5-fluoro-1,2-di-hidro-2-oxo-3hindol- 3-ilideno)metil-2,4-dimetil-1h-pirrol-3-carboxamida, processos para a sua preparação e suas composições PT1419151E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31235301P 2001-08-15 2001-08-15

Publications (1)

Publication Number Publication Date
PT1419151E true PT1419151E (pt) 2014-03-27

Family

ID=23211067

Family Applications (2)

Application Number Title Priority Date Filing Date
PT2759342T PT1419151E (pt) 2001-08-15 2002-08-13 Cristais que incluem um sal do ácido málico de n-[2- (dietilamino)etil]-5-[(5-fluoro-1,2-di-hidro-2-oxo-3hindol- 3-ilideno)metil-2,4-dimetil-1h-pirrol-3-carboxamida, processos para a sua preparação e suas composições
PT16196036T PT3168218T (pt) 2001-08-15 2002-08-13 Um cristal compreendendo um sal de ácido l-málico de n-[2- (dietilamino)etil]-5-[(5-fluoro-1,2-dihidro-2-oxo-3h-indol- 3-ilideno)metil]-2,4-dimetil-1h-pirrol-3-carboxamida para utilização como um medicamento

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT16196036T PT3168218T (pt) 2001-08-15 2002-08-13 Um cristal compreendendo um sal de ácido l-málico de n-[2- (dietilamino)etil]-5-[(5-fluoro-1,2-dihidro-2-oxo-3h-indol- 3-ilideno)metil]-2,4-dimetil-1h-pirrol-3-carboxamida para utilização como um medicamento

Country Status (42)

Country Link
US (2) US20030069298A1 (enExample)
EP (3) EP3168218B1 (enExample)
JP (1) JP4159988B2 (enExample)
KR (1) KR100639281B1 (enExample)
CN (2) CN100364991C (enExample)
AP (1) AP1660A (enExample)
AR (1) AR036261A1 (enExample)
AU (1) AU2002324684B2 (enExample)
BG (1) BG108553A (enExample)
BR (1) BR0211612A (enExample)
CA (1) CA2455050C (enExample)
CO (1) CO5550431A2 (enExample)
CU (1) CU23713B7 (enExample)
CY (1) CY1121552T1 (enExample)
CZ (1) CZ2004196A3 (enExample)
DK (2) DK3168218T3 (enExample)
EA (1) EA006445B9 (enExample)
EC (1) ECSP044975A (enExample)
ES (3) ES2623094T3 (enExample)
GE (1) GEP20063777B (enExample)
HR (1) HRP20040112B1 (enExample)
HU (1) HU229206B1 (enExample)
IL (1) IL160097A0 (enExample)
IS (1) IS7147A (enExample)
MA (1) MA27058A1 (enExample)
ME (1) ME00414B (enExample)
MX (1) MXPA04001452A (enExample)
MY (1) MY139383A (enExample)
NO (1) NO326508B1 (enExample)
NZ (1) NZ531232A (enExample)
OA (1) OA12650A (enExample)
PL (1) PL216524B1 (enExample)
PT (2) PT1419151E (enExample)
RS (1) RS53251B (enExample)
SI (2) SI3168218T1 (enExample)
SK (1) SK902004A3 (enExample)
TN (1) TNSN04028A1 (enExample)
TR (1) TR201900509T4 (enExample)
TW (1) TWI269796B (enExample)
UA (1) UA76483C2 (enExample)
WO (1) WO2003016305A1 (enExample)
ZA (1) ZA200400706B (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA006445B9 (ru) 2001-08-15 2017-02-28 Фармация Энд Апджон Компани Кристаллы, содержащие соль яблочной кислоты n-[2-(диэтиламино)этил]-5-[(5-фторо-2-оксо-1,2-дигидро-3h-индол-3-илиден)метил]-2,4-диметил-1h-пиррол-3-карбоксамида, способы их получения и их композиции
TW200418836A (en) * 2002-09-10 2004-10-01 Pharmacia Italia Spa Formulations comprising an indolinone compound
NZ546001A (en) * 2003-10-02 2009-09-25 Pharmacia & Upjohn Co Llc Salts and polymorphs of a pyrrole-substituted indolinone compound
US20060009510A1 (en) * 2004-07-09 2006-01-12 Pharmacia & Upjohn Company Llc Method of synthesizing indolinone compounds
ATE480534T1 (de) * 2004-07-22 2010-09-15 Lilly Co Eli Kristallines variables hydrat von (s)-6-(4-(2-((3-(9h-carbazol-4-yloxy)-2-hydroxy ropyl)amino)-2- methylpropyl)phenoxy)-3-pyridincarbonsäureamid- hemisuccinatsalz
CA2603445A1 (en) * 2005-05-12 2006-11-16 Pfizer Inc. Anticancer combination therapy using sunitinib malate
CN103601720B (zh) 2005-09-19 2016-08-10 硕腾服务有限责任公司 经吡咯取代的2-吲哚酮的固态盐形式
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
US20100256392A1 (en) * 2007-11-21 2010-10-07 Teva Pharmaceutical Industries Ltd. Polymorphs of sunitinib base and processes for preparation thereof
WO2009067674A2 (en) * 2007-11-21 2009-05-28 Teva Pharmaceutical Industries Ltd. Polymorphs of sunitinib base and processes for preparation thereof
CA2709083A1 (en) * 2007-12-12 2009-06-18 Medichem S.A. Polymorphic forms of a 3-pyrrole substituted 2-indolinone
EP2090306A1 (en) 2008-02-13 2009-08-19 Ratiopharm GmbH Pharmaceutical compositions comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
EP2113248A1 (en) 2008-04-29 2009-11-04 Ratiopharm GmbH Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide
EP2252607A2 (en) * 2008-02-21 2010-11-24 Generics [UK] Limited Novel polymorphs and processes for their preparation
EP2098521A1 (en) * 2008-03-06 2009-09-09 Ratiopharm GmbH Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation
ES2391501T3 (es) * 2008-03-31 2012-11-27 Teva Pharmaceutical Industries Ltd. Procedimientos para preparar sunitinib y sales del mismo
EP2280960A1 (en) 2008-04-16 2011-02-09 Natco Pharma Limited Novel polymorphic forms of sunitinib base
US8829039B2 (en) 2008-05-23 2014-09-09 Shanghai Institute Of Pharmaceutical Industry Dihydroindolinone derivatives
SI2313371T1 (sl) * 2008-06-13 2013-02-28 Medichem, S.A. Postopek za pripravo soli 3-pirol substituirane 2-indolinonske jabolčne kisline
EP2138167A1 (en) 2008-06-24 2009-12-30 ratiopharm GmbH Pharmaceutical composition comprising N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
WO2009156837A2 (en) * 2008-06-26 2009-12-30 Medichem, S.A. Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt
CA2730079A1 (en) * 2008-07-10 2010-01-14 Generics [Uk] Limited Processes for the preparation of crystalline forms of sunitinib malate
WO2010010454A2 (en) 2008-07-24 2010-01-28 Medichem, S.A. Crystalline forms of a 3-pyrrole substituted 2-indolinone malate salt
WO2010011834A2 (en) * 2008-07-24 2010-01-28 Teva Pharmaceutical Industries Ltd. Sunitinib and salts thereof and their polymorphs
CA2734965A1 (en) * 2008-08-25 2010-03-04 Generics [Uk] Limited Novel crystalline form and processes for its preparation
CA2735084A1 (en) * 2008-08-25 2010-03-04 Generics [Uk] Limited Novel polymorphs of sunitinib and processes for their preparation
WO2010041134A1 (en) * 2008-10-10 2010-04-15 Medichem, S.A. Process for preparing a 3-pyrrole subsituted 2-indolinone malate salt
EP2181991A1 (en) * 2008-10-28 2010-05-05 LEK Pharmaceuticals D.D. Novel salts of sunitinib
EP2186809A1 (en) * 2008-11-13 2010-05-19 LEK Pharmaceuticals D.D. New crystal form of sunitinib malate
US8329740B2 (en) 2009-01-02 2012-12-11 Hetero Research Foundation Polymorphs of sunitinib malate
EA038195B1 (ru) 2009-01-16 2021-07-22 Экселиксис, Инк. Малатная соль n-(4-{[6,7-бис-(метилокси)хинолин-4-ил]окси}фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида и ее применение для лечения рака почек и печени
EP2255792A1 (en) 2009-05-20 2010-12-01 Ratiopharm GmbH Pharmaceutical compositions for N-[2-(Diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1H-pyrrole-3-carboxamide
WO2011004200A1 (en) 2009-07-10 2011-01-13 Generics [Uk] Limited Novel pyrrole derivatives
WO2011033472A1 (en) 2009-09-16 2011-03-24 Ranbaxy Laboratories Limited Salts of sunitinib
US20120271056A1 (en) 2009-11-12 2012-10-25 Ranbaxy Laboratories Limited Process for the preparation of crystalline form i of l-malic acid salt of sunitinib
US8916716B2 (en) 2009-11-19 2014-12-23 Ranbaxy Laboratories Limited Process for the preparation of crystalline form II of L-malic acid salt of sunitinib
WO2011092664A1 (en) 2010-01-29 2011-08-04 Ranbaxy Laboratories Limited Crystalline forms of l-malic acid salt of sunitinib
WO2011100325A2 (en) 2010-02-09 2011-08-18 Sicor Inc. Polymorphs of sunitinib salts
WO2011104555A2 (en) 2010-02-25 2011-09-01 Generics [Uk] Limited Novel process
US20130123511A1 (en) 2010-03-04 2013-05-16 Ranbaxy Laboratories Limited Process for the direct preparation of malic acid salt of sunitinib
WO2011114246A1 (en) 2010-03-18 2011-09-22 Ranbaxy Laboratories Limited Process for the preparation of malic acid salt of sunitinib
WO2011128699A2 (en) 2010-04-16 2011-10-20 Generics [Uk] Limited Novel process
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
ES2724801T3 (es) 2011-04-19 2019-09-16 Pfizer Combinaciones de anticuerpos anti-4-1BB y anticuerpos inductores de ADCC para el tratamiento del cáncer
EP2828251B1 (en) 2012-03-23 2018-10-31 Laurus Labs Limited An improved process for the preparation of sunitinib and its acid addition salts thereof
PL399027A1 (pl) 2012-04-27 2013-10-28 Instytut Farmaceutyczny Sposób otrzymywania N-[2-(dietylamino)etylo]-5-formylo-2,4-dimetylo-1H-pirolo-3-karboksyamidu o wysokiej czystosci i jego zastosowanie do wytwarzania sunitynibu
CN105457021A (zh) 2012-05-04 2016-04-06 辉瑞公司 前列腺相关抗原及基于疫苗的免疫治疗疗法
CA2838585A1 (en) 2013-10-18 2015-04-18 Hari Babu Matta An ascorbic acid salt of sunitinib
US9604968B2 (en) 2013-10-18 2017-03-28 Sun Pharmaceutical Industries Limited Pure crystalline Form II of L-malic acid salt of sunitinib and processes for its preparation
KR102006527B1 (ko) 2013-11-01 2019-08-02 화이자 인코포레이티드 전립선-연관 항원의 발현을 위한 벡터
CN104693187A (zh) * 2013-12-10 2015-06-10 安杰世纪生物科技（北京）有限公司 一种舒尼替尼L-苹果酸盐晶型λ及其制备方法
CN104744442B (zh) * 2013-12-25 2019-05-28 江苏豪森药业集团有限公司 苹果酸舒尼替尼的制备方法
RU2567535C1 (ru) * 2014-10-01 2015-11-10 Олег Ростиславович Михайлов КРИСТАЛЛИЧЕСКАЯ ε-МОДИФИКАЦИЯ N-[2-(ДИЭТИЛАМИНО)ЭТИЛ]-5-[(Z)-(5-ФТОР-1,2-ДИГИДРО-2-ОКСО-3Н-ИНДОЛ-3-ИЛИДЕН)МЕТИЛ]-2,4-ДИМЕТИЛ-1Н-ПИРРОЛ-3-КАРБОКСАМИД МАЛАТА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЕ ОСНОВЕ
CN105712979A (zh) * 2014-12-05 2016-06-29 广州白云山医药集团股份有限公司白云山制药总厂 一种苹果酸舒尼替尼晶型ⅰ的制备方法
EP3539536A1 (en) 2018-03-15 2019-09-18 MH10 Spolka z ograniczona odpowiedzialnoscia A pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form i
WO2020216450A1 (en) 2019-04-25 2020-10-29 Synthon B.V. Pharmaceutical composition comprising amorphous sunitinib
JP2022529290A (ja) * 2019-04-18 2022-06-20 メーター ヘルス インコーポレイテッド 呼吸性不整脈を処置するための方法および組成物
JP7633786B2 (ja) * 2020-09-18 2025-02-20 日本化薬株式会社 スニチニブリンゴ酸塩を有効成分とする医薬錠剤
KR20240025990A (ko) 2022-08-19 2024-02-27 주식회사 스카이테라퓨틱스 무정형 수니티닙, 그 제조방법 및 이를 포함한 의약 조성물

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL169987B1 (en) 1990-10-15 1996-09-30 Pfizer Method of obtaining novel indole derivatives
IL100091A (en) 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation
DK0573221T3 (da) 1992-06-05 1998-10-07 Merck Sharp & Dohme Sulfatsaltet af en substitueret triazol, farmaceutiske præparater deraf og deres anvendelse i terapi
NZ263002A (en) * 1993-03-12 1996-12-20 Upjohn Co Crystalline ceftiofur {namely: 7-[2-(2-amino-1,3-thiazol-4-yl)- 2-methoxyimino)acetamido]-3-[(fur-2-ylcarbonyl)thiomethyl]- 3-cephem-4-carboxylic acid} in free acid form
US6329364B1 (en) 1994-08-31 2001-12-11 Eli Lilly And Company Crystalline form of dihydro-2,3-benzodiazepine derivative
DE19503966C2 (de) 1995-02-07 1998-07-02 Mack Chem Pharm Kristallmodifikation von 2,4-Diamino-6-hydroxymethylpteridin-Hydrobromid, Verfahren zu dessen Herstellung und dessen Verwendung
US5597663A (en) * 1995-05-30 1997-01-28 Motorola, Inc. Low temperature molten lithium salt electrolytes for electrochemical cells
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5673451A (en) * 1995-07-06 1997-10-07 Moore; James R. Instructional toothbrush
US20020038021A1 (en) 1995-12-11 2002-03-28 Barton Kathleen P. Eplerenone crystalline form exhibiting enhanced dissolution rate
US20020045746A1 (en) 1995-12-11 2002-04-18 Barton Kathleen P. Eplerenone crystalline form
US6066647A (en) 1996-07-29 2000-05-23 Pfizer Inc. Zwitterionic forms of trovafloxacin
AU722072B2 (en) 1996-08-14 2000-07-20 G.D. Searle & Co. Crytalline form of 4-(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonamide
US6251355B1 (en) 1996-12-25 2001-06-26 Nippon Kayaku Kabushiki Kaisha Fine cisplatin powder and process for the production thereof
US5777185A (en) * 1997-09-09 1998-07-07 Laroche Industries Inc. Production of organic fluorine compounds
US6133305A (en) * 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
US6012678A (en) * 1998-01-26 2000-01-11 The Boeing Company Galley vacuum waste disposal system
ID25775A (id) 1998-06-19 2000-11-02 Teijin Ltd Polimorf dari asam 2-(3-siano-4-isobutiloksifenil)-4-metil-5-tiazol karboksilat dan metoda pembuatannya
TR200101860T2 (tr) * 1998-12-17 2001-12-21 F.Hoffmann-La Roche Ag Sikline bağlı kinaz inhibitörleri olarak 4-alkenil (ve alkinil) oksidoller
US6239141B1 (en) 1999-06-04 2001-05-29 Pfizer Inc. Trovafloxacin oral suspensions
ATE514676T1 (de) * 1999-11-24 2011-07-15 Sugen Inc Ionisierbare indolinon derivate und deren verwendung als ptk liganden
CN1329390C (zh) * 2000-02-15 2007-08-01 苏根公司 吡咯取代的2－二氢吲哚酮蛋白激酶抑制剂
US6316672B1 (en) 2001-01-31 2001-11-13 Grayson Walker Stowell Form a of fluoxetine hydrochloride
EA006445B9 (ru) 2001-08-15 2017-02-28 Фармация Энд Апджон Компани Кристаллы, содержащие соль яблочной кислоты n-[2-(диэтиламино)этил]-5-[(5-фторо-2-оксо-1,2-дигидро-3h-индол-3-илиден)метил]-2,4-диметил-1h-пиррол-3-карбоксамида, способы их получения и их композиции
EP2252607A2 (en) 2008-02-21 2010-11-24 Generics [UK] Limited Novel polymorphs and processes for their preparation
WO2009156837A2 (en) 2008-06-26 2009-12-30 Medichem, S.A. Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt

Also Published As

Publication number Publication date
KR100639281B1 (ko) 2006-10-31
US20030069298A1 (en) 2003-04-10
PT3168218T (pt) 2019-01-11
DK1419151T3 (da) 2014-03-31
CY1121552T1 (el) 2020-05-29
EP2332934A1 (en) 2011-06-15
TNSN04028A1 (fr) 2006-06-01
KR20040030074A (ko) 2004-04-08
CN1789264A (zh) 2006-06-21
AU2002324684B2 (en) 2006-10-05
EA006445B9 (ru) 2017-02-28
NO20041054L (no) 2004-03-12
HUP0700036A2 (en) 2008-10-28
ES2705063T3 (es) 2019-03-21
JP2005503386A (ja) 2005-02-03
AP2004002976A0 (en) 2004-03-31
IS7147A (is) 2004-02-10
OA12650A (en) 2006-06-19
ZA200400706B (en) 2005-05-25
ECSP044975A (es) 2004-03-23
CZ2004196A3 (cs) 2005-01-12
CU20040029A7 (es) 2008-03-14
EP1419151A1 (en) 2004-05-19
EP2332934B1 (en) 2017-03-01
IL160097A0 (en) 2004-06-20
MA27058A1 (fr) 2004-12-20
BG108553A (bg) 2005-04-30
EA006445B1 (ru) 2005-12-29
CA2455050C (en) 2007-02-20
ME00414B (me) 2011-10-10
EP1419151B1 (en) 2014-02-26
CA2455050A1 (en) 2003-02-27
NZ531232A (en) 2004-11-26
NO326508B1 (no) 2008-12-15
BR0211612A (pt) 2004-08-24
HU229206B1 (en) 2013-09-30
HK1088008A1 (zh) 2006-10-27
HRP20040112B1 (en) 2012-03-31
CN100439360C (zh) 2008-12-03
EP3168218B1 (en) 2018-11-14
ES2623094T3 (es) 2017-07-10
SI1419151T1 (sl) 2014-04-30
AP1660A (en) 2006-09-09
CN100364991C (zh) 2008-01-30
HRP20040112A2 (en) 2004-06-30
GEP20063777B (en) 2006-03-27
WO2003016305A1 (en) 2003-02-27
SI3168218T1 (sl) 2019-05-31
UA76483C2 (en) 2006-08-15
CU23713B7 (es) 2011-10-05
TWI269796B (en) 2007-01-01
CN1543462A (zh) 2004-11-03
EA200400183A1 (ru) 2004-08-26
HK1066542A1 (en) 2005-03-24
JP4159988B2 (ja) 2008-10-01
US7435832B2 (en) 2008-10-14
ES2453164T3 (es) 2014-04-04
PL216524B1 (pl) 2014-04-30
RS10304A (sr) 2007-02-05
DK3168218T3 (en) 2019-01-14
CO5550431A2 (es) 2005-08-31
SK902004A3 (sk) 2005-03-04
EP3168218A1 (en) 2017-05-17
MXPA04001452A (es) 2004-05-20
MY139383A (en) 2009-09-30
PL368317A1 (en) 2005-03-21
TR201900509T4 (tr) 2019-02-21
AR036261A1 (es) 2004-08-25
RS53251B (sr) 2014-08-29
US20070191458A1 (en) 2007-08-16

Similar Documents

Publication Publication Date Title
PT1419151E (pt) Cristais que incluem um sal do ácido málico de n-[2- (dietilamino)etil]-5-[(5-fluoro-1,2-di-hidro-2-oxo-3hindol- 3-ilideno)metil-2,4-dimetil-1h-pirrol-3-carboxamida, processos para a sua preparação e suas composições
NO2019005I1 (no) N-[2-(dietylamino)etyl]-5-[(Z)-(5-fluoro-2-okso-1,2-dihydro-3H-indol-3-yliden)metyl]-2,4-dimetyl-1H-pyrrol-3-karboksamid (sunitinib), samt farmasøytisk akseptable salter
IL189359A0 (en) Novel process for the synthesis of 5 - (4 - fluorophenyl) - 1 - [2 - ((2r, 4r)- 4 - hydroxy - 6 - oxo -tetrahydro - pyran - 2 - yl) - ethyl] - 2 - isopropyl- 4 - phenyl - 1h - pyrrole - 3 - carboxylic acid phenylamide
EP1619180A4 (en) CASR ANTAGONIST
IL156055A (en) Crystal form viii of atorvastatin hemi- calcium, processes for its preparation and pharmaceutical composition comprising atorvastatin hemi-calcium form viii
ZA200700765B (en) Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol
IL215094A (en) Methyl [1– {2– [5– (10– {2– [1– {2– [Methoxycarbonyl) Amino] –3 – Methylbutanoyl} pyrrolidin-2-yl] - h1– Amidazole-5-Ill} –6– Phenylindolo [2,1- c] [3,1] benzoxazine-3-yl) - h 1-amidazole-2-yl] pyrrolidin-1-yl} -3-methyl-1-oxobutan-2-yl] carbamate and preparations Hcv delay pharmacy containing it
IL176236A (en) Heterocyclic compounds, pharmaceuticals containing them and their use in the preparation of drugs
IL198996A (en) Use of a tyrosine kinase inhibitor for its preparation as a medicinal preparation
MX2007014892A (es) Formas polimorficas del ester etilico del acido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}- 1-metil-h-bencimidazol-5-carbonil)-piridin-2-il--amino]propionico .
ZA200101821B (en) Use of heteroaryl substituted n-(indole-2-carbonyl-) amides for treatment of infection.
IL185035A0 (en) Derivatives of n-[(4,5-diphenyl-3-alkyl-2-thienyl) methyl] amine
IL166621A0 (en) Polymorph of n-methyl-n-(3-ä-3-Ä2-thienylcarbonylÜ-pyrazol-Ä1,5-alphaÜpyrimidin-7-ylüacetamide and pharmaceutical compositions containing the same
EE05242B1 (et) 5-kloro-3-(4-metaansulfonlfenl)-6'-metl[2,3']bipridinli polmorfne vorm, selle valmistamismeetod, kasutamine ja farmatseutiline kompositsioon
PT1600441E (pt) Forma cristalina de cloridrato de lercanidipina para utilização como agente anti-hipertensor
PL1771069T3 (pl) Pochodne N-(2-(hydroksymetylo)fenylo)-1H-pirazolo-4-karboksamidu i związki pokrewne jako mikrobójcze substancje czynne do zastosowania w ochronie roślin i materiałów
ZA200500203B (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same
DE50305374D1 (de) Neue prodrugs von 1-methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carbonsäure-(n -2-pyridil-n-2-hydroxycarbonylethyl)-amid, ihre herstellung und ihre verwendung als arzneimittel
PL375415A1 (en) Process for preparing 5-(4-fluorophenyl)-1-[2-((2r,4r)-4-hydroxy -6-oxo-tetrahydro-pyran-2-yl)ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide
AU1479800A (en) Procedure for synthesis of N-(2(((5-((dialkilamino) methyl)-2- furanyl) methyl)thyo) ethyl)-N'- alkyl-2-nitro1,1 alkenediamines and their hydrochlorides
AR034621A1 (es) Formulaciones
AU2002245958A1 (en) Preparation of formulations of angiotensin ii at1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications
AU2002356352A1 (en) Use of 5-chloro-4-(3-(n-(2-(3,4-dimethoxy-phenyl)-ethyl)-n-methylamino)-propylamino)-3-(2h)-pyridazinone as metabolic modulator
TH69655A (th) ผลึกซึ่งประกอบด้วยเกลือของกรดมาลิคของ 3-ไพร์รอล ซับสทิทิวเทด 2-อินโดลิโนน และสารผสมของสารเหล่านี้